Cargando…
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010939/ https://www.ncbi.nlm.nih.gov/pubmed/29930467 http://dx.doi.org/10.3748/wjg.v24.i23.2457 |